BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/5/2017 12:48:27 AM | Browse: 926 | Download: 1197
Publication Name World Journal of Gastroenterology
Manuscript ID 35865
Country/Territory Greece
Received
2017-08-19 01:27
Peer-Review Started
2017-08-19 06:47
To Make the First Decision
2017-08-30 00:06
Return for Revision
2017-09-04 06:14
Revised
2017-09-18 04:11
Second Decision
2017-09-25 06:03
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2017-09-28 18:03
Articles in Press
2017-09-28 18:03
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2017-10-23 07:43
Publish the Manuscript Online
2017-11-05 00:48
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Retrospective Cohort Study
Article Title Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease
Manuscript Source Invited Manuscript
All Author List Athanasios Kostas, Spyros I Siakavellas, Charalambos Kosmidis, Anna Takou, Joanna Nikou, Georgios Maropoulos, John Vlachogiannakos, George V Papatheodoridis, Ioannis Papaconstantinou and Giorgos Bamias
ORCID
Author(s) ORCID Number
Athanasios Kostas http://orcid.org/0000-0002-4411-710X
Spyros I Siakavellas http://orcid.org/0000-0001-8217-8950
Charalambos Kosmidis http://orcid.org/0000-0002-2734-8475
Anna Takou http://orcid.org/0000-0002-2924-9681
Joanna Nikou http://orcid.org/0000-0003-4289-6661
Georgios Maropoulos http://orcid.org/0000-0001-7545-120X
John Vlachogiannakos http://orcid.org/0000-0001-9291-0711
George V Papatheodoridis http://orcid.org/0000-0002-3518-4060
Ioannis Papaconstantinou http://orcid.org/0000-0002-4614-9041
Giorgos Bamias http://orcid.org/0000-0002-5492-5717
Funding Agency and Grant Number
Corresponding Author Giorgos Bamias, MD, PhD, Associate Professor, Doctor, Academic Department of Gastroenterology, University of Athens Medical School, Laiko Genreral Hospital, 17 Agiou Thoma Street, Athens 11527, Greece. gbamias@gmail.com
Key Words Fecal calprotectin; Biomarker; Inflammatory bowel disease; Mucosal healing; Clinical outcome; Relapse; Ulcerative colitis; Crohn’s disease
Core Tip Fecal calprotectin (FC) is a novel biomarker aiming to facilitate the assessment of inflammatory bowel disease (IBD) activity as its expression is driven by the presence of intestinal inflammation. Our present retrospective study provides evidence that FC measurement during clinical remission may be helpful in identifying early those cases with a higher risk of recurrence. Moreover, lower FC values seem to correlate with endoscopic quiescence of the disease. Thus, FC monitoring may be effective in recognizing distinct subgroups of IBD patients offering the opportunity to the clinician to tailor their management accordingly in order to achieve optimal disease control.
Publish Date 2017-11-05 00:48
Citation Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, Vlachogiannakos J, Papatheodoridis GV, Papaconstantinou I, Bamias G. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(41): 7387-7396
URL http://www.wjgnet.com/1007-9327/full/v23/i41/7387.htm
DOI http://dx.doi.org/10.3748/wjg.v23.i41.7387
Full Article (PDF) WJG-23-7387.pdf
Full Article (Word) WJG-23-7387.doc
Manuscript File 35865-Review.docx
Answering Reviewers 35865-Answering reviewers.pdf
Audio Core Tip 35865-Audio core tip.wav
Biostatistics Review Certificate 35865-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form 35865-Conflict-of-interest statement.pdf
Copyright License Agreement 35865-Copyright assignment.pdf
Data Sharing Statement 35865-Data sharing statement.pdf
Signed Informed Consent Form(s) or Document(s) 35865-Informed consent statement.pdf
Institutional Review Board Approval Form or Document 35865-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 35865-Language certificate.pdf
Scientific Research Process 35865-Scientific research process.pdf
Peer-review Report 35865-Peer-review(s).pdf
Scientific Misconduct Check 35865-Scientific misconduct check.pdf
Scientific Editor Work List 35865-Scientific editor work list.pdf